
"Dear Health Professional" Letter Warns on Phosphocol P 32

Phosphocol P 32, a radiopharmaceutical approved for the intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, has added a warning statement in the package insert regarding the increased risk for leukemia in certain situations.

Additionally, the post-marketing experience identified radiation injury (necrosis and fibrosis) to the small bowel, cecum and bladder following administration of P 32 into the peritoneal cavity, the company said.

Healthcare professionals should refer to the product's revised prescribing information for updated information regarding the appropriate use of Phosphocol P 32.

Published on : Fri, 19 Sep 2008